[
  {
    "ts": null,
    "headline": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
    "summary": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
    "url": "https://finnhub.io/api/news?id=5396dc50bae2cf88fb2cad0e40ff1bb7979c1a7a66573670cb244f4dcfa85011",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743321600,
      "headline": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
      "id": 133610520,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5396dc50bae2cf88fb2cad0e40ff1bb7979c1a7a66573670cb244f4dcfa85011"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
    "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
    "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743310800,
      "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
      "id": 133598030,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
      "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Opportunities Fund Q4 2024 Commentary",
    "summary": "The equity portion of the Abrdn Healthcare Opportunities Fund fell (gross) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=a5933eccf4e0954a3d6ef92d4832f42825c89b4de8dd9bba832d8a1bb2aa2d23",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743305100,
      "headline": "abrdn Healthcare Opportunities Fund Q4 2024 Commentary",
      "id": 133592692,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1409312575/image_1409312575.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The equity portion of the Abrdn Healthcare Opportunities Fund fell (gross) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=a5933eccf4e0954a3d6ef92d4832f42825c89b4de8dd9bba832d8a1bb2aa2d23"
    }
  }
]